{
  "id": 10724336,
  "title": "UniQure tumbles with latest data for Huntington’s gene therapy",
  "url": "https://urgent.news/2026/09/29/uniqure-tumbles-with-latest-data-for-huntingtons-gene-therapy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-29T15:36:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Analysts guessed that investors wanted to see stronger durability results at a four-year check-in of the key trial supporting a potential approval of \"AMT-130.\"",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 3,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years",
        "url": "https://urgent.news/2026/09/29/stat-uniqures-gene-therapy-continues-to-slow-huntingtons-progression",
        "published": "2026-09-29T11:05:00.000Z"
      },
      {
        "outlet": "Endpoints News",
        "title": "UniQure sinks as Huntington's gene therapy appears to show waning benefit over time",
        "url": "https://urgent.news/2026/09/29/uniqure-sinks-as-huntingtons-gene-therapy-appears-to-show-waning",
        "published": "2026-09-29T14:23:49.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}